ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 899

Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout

Lisa Stamp1, Yuqing Zhang 2, Christopher Frampton 3, Jill Drake 3, Peter Chapman 4, Stephen Duffull 5 and Tuhina Neogi 6, 1University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, 2Massachusetts General Hospital, Boston, MA, 3University of Otago, Christchurch, Christchurch, New Zealand, 4Christchurch Hospital, Christchurch, New Zealand, 5University of Otago, Dunedin, New Zealand, 6Boston University School of Medicine, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: gout and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S102: Metabolic & Crystal Arthropathies I: Clinical (898–902)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: In small studies, cherries and cherry concentrate have been suggested to reduce serum urate and gout flares. The aims of this study were to determine the magnitude of the effect of tart cherry concentrate on serum urate in people with gout, the most effective dose of tart cherry concentrate in lowering serum urate, and adverse effects with tart cherry concentrate.

Methods: Fifty people with gout as defined by ARA preliminary classification criteria for gout AND a serum urate >6mg/dl (0.36mmol/l) were recruited. People with type 2 diabetes and those receiving diuretics were excluded. Half the participants were already receiving allopurinol and half were on no urate lowering therapy at the time of recruitment, and participants in each of these blocks were randomised into 5 Cherryvite montmorency tart cherry juice concentrate groups: placebo, 7.5mls twice daily, 15mls twice daily, 22.5mls twice daily and 30mls twice daily for 28 days. Participants were commenced on tart cherry concentrate and blood samples were taken at baseline, the 1, 3, and 5 hours post cherry and then day 1, 3, 7, 14, 21 and 28. Urine anthocyanin concentrations were determined by HPLC as a measure of compliance at before any cherry concentrate day 0 and 28. AUC for serum urate was calculated over the 28-day study period.

Results: Cherry concentrate dose had no significant effect on reduction in serum urate AUC over the 28-day study period. There was no influence of cherry concentrate on the urate lowering effect of allopurinol. There was no effect of cherry concentrate dose on change in urinary anthocyanin between day 0 and day 28 (table). However, those receiving allopurinol had significantly greater increases in urinary anthocyanins (p< 001). Cherry concentrate dose had no significant effect on urinary urate excretion as measured by Simkin Index (p=0.53) or fractional excretion of urate (p=0.32). There were 24 adverse events over the 28 day period with only one (hyperglycaemia) considered possibly related to cherry concentrate. There was no significant effect of cherry concentrate on change in HbA1c (p=0.68) or weight (p=0.80) over the 28 days. There was no effect of cherry concentrate on the frequency of gout flares over the 28-day study period p=0.76) (table).

Conclusion: Tart cherry concentrate had no effect on serum urate or urine urate excretion over 28 days. Reassuringly there were few adverse events. If there is an effect of cherry concentrate on gout flares over a longer time period it is not likely to be mediated by reduction in serum urate.


Table

Table: Effect of cherry concentrate


Disclosure: L. Stamp, None; Y. Zhang, None; C. Frampton, None; J. Drake, None; P. Chapman, None; S. Duffull, None; T. Neogi, MerckSerono, 5, Novartis, 5.

To cite this abstract in AMA style:

Stamp L, Zhang Y, Frampton C, Drake J, Chapman P, Duffull S, Neogi T. Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/lack-of-effect-of-tart-cherry-concentrate-dose-on-serum-urate-in-people-with-gout/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lack-of-effect-of-tart-cherry-concentrate-dose-on-serum-urate-in-people-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology